Neurotech Pharmaceuticals, Inc.: FDA Greenlights Mazzo's Neurotech Implant

Neurotech Pharmaceuticals, Inc.: FDA Approves Neurotech's ENCELTO, First for Macular Telangiectasia Type 2

Neurotech Pharmaceuticals, Inc.: Mazzo's Neurotech Gets FDA Approval for Retinal Disease Treatment

Neurotech Pharmaceuticals, Inc.: Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Neurotech Pharmaceuticals, Inc.: Neurotech Pharmaceuticals Receives Priority Review of Biologics License Application From the FDA for Treatment of Retinal Disease

Neurotech Pharmaceuticals, Inc.: Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

Neurotech Pharmaceuticals, Inc.: Phase III clinical trials with NT 501 ECT showed statistical significance for the primary endpoint in Macular telangiectasia type 2

Press Release: Neurotech : Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2

Neurotech: Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results

Neurotech: Neurotech Announces Positive Phase II Results In NT-501 (CNTF) For Macular Telangiectasia